50results about How to "Reduces levels of oxidative stress" patented technology

The invention discloses lactobacillus paracasei capable of relieving alcoholic intestinal injury and an application of the lactobacillus paracasei capable of relieving alcoholic intestinal injury, andbelongs to the technical field of microorganisms and medicines, The invention provides a medicine capable of preventing and / or treating alcoholic intestinal injury or alcoholic liver injury. Effective components of the medicine are lactobacillus paracasei CCFM1120, and the lactobacillus paracasei CCFM1120 can effectively relieve the alcoholic intestinal injury and the alcoholic liver injury. Thelactobacillus paracasei has the specific effects that the mRNA expression level of intestine tight junction proteins of alcohol modeled mice can be notably increased, the content of endotoxin in serumof the alcohol modeled mice can be notably reduced, the activity of alanine aminotransferase and aspartate aminotransferase in the serum of the alcohol modeled mice can be notably reduced, the oxidation stress level of the liver of the alcohol modeled mice can be notably reduced, and the pathology damage of liver tissue of the alcohol modeled mice can be notably improved.

The invention belongs to the technical field of biological materials and biological medicines, and discloses an oxidase-loaded microneedle for promoting wound healing of diabetics and a preparation method thereof.The preparation method comprises the steps that SilMA is dissolved in deionized water, and a photoinitiator HMPP is added under the dark condition to obtain a mixed solution A; adding PBZs and VEGF solution into the mixed solution A to obtain a mixed solution B; adding the mixed solution A into a polymyxin solution to obtain a mixed solution C; and respectively adding the mixed solution B and the mixed solution C into a microneedle mold, carrying out crosslinking under ultraviolet light, and separating the mold to obtain the composite microneedle. The PBZs and the VEGF are creatively loaded into the SilMA composite hydrogel microneedle to treat diabetic skin wounds, the oxidative stress level of diabetic skin wound tissues can be effectively relieved, a proper oxidation microenvironment is provided for the VEGF to play a role in promoting angiogenesis, and healing of the diabetic skin wounds can be better promoted.

The invention relates to a controlled-release nano medicine available for targeted application to neurodegenerative diseases, in particular to a nano particle. The nano particle comprises a carrier material, active components and target modules, wherein the carrier material is human serum albumin, and the active components are capable of preventing and / or treating the neurodegenerative diseases. The invention further relates to a nano particle preparation method, a nano-particle-containing pharmaceutical composition and application of the nano particle or the pharmaceutical composition to preparation of medicines for preventing and / or treating the neurodegenerative diseases of subjects.

The invention relates to a preparation method of a polycaprolactone nerve scaffold loaded with fullerol. The method comprises the following steps: uniformly mixing a polycaprolactone solution and a fullerol solution, and injecting the mixture into an electrostatic spinning device to prepare a fullerol-loaded polycaprolactone electrospun film; then preparing the polycaprolactone electrospun film loaded with fullerol into a hollow tubular stent with the wall thickness of 0.4-1.2 mm, and forming a plurality of through holes with the diameter of 10-30 [mu] m in the tube wall, thereby obtaining the polycaprolactone nerve stent loaded with fullerol. The inner diameter of the polycaprolactone nerve scaffold loaded with fullerol is 1.5 mm to 7 mm, and the length of the polycaprolactone nerve scaffold loaded with fullerol is 2 cm to 3 cm. The preparation method is simple, the size is controllable, and the material requirement is low; the polycaprolactone nerve scaffold disclosed by the invention can simulate an extracellular matrix structure, reduce the oxidative stress level in a peripheral nerve injury repair process and promote peripheral nerve regeneration; meanwhile, the mechanical strength can be increased, the degradation time can be prolonged, and nutrition exchange between defective peripheral nerves and peripheral tissues outside the tube wall is facilitated.

The invention discloses an application of bioactive polypeptide PACAP in preparation of drugs for improving fertility of obese men, and belongs to the field of damaged fertility diseases of the obesemen. The bioactive polypeptide PACAP drugs provided by the invention can significantly prevent and relieve obesity-induced male fertility damage (mainly by improving blood lipid and sex hormone levels, reducing a testicular tissue oxidative stress level, improving obesity-induced testicular spermatogenic cell damage, inhibiting high lipid-induced apoptosis of spermatogonia GC-1, and improving sperm function and early embryo quality after in-vitro fertilization), and repair pathological change and reproductive system function of fertility damage of the obese men, the relationship between obesity and male infertility can be initially understood, the protective effect of the PACAP on obesity-induced male reproductive damage can be clarified, and a theoretical basis, an experimental basis anda targeted treatment strategy are provided for clinical diagnosis and treatment of obese male infertility.

The invention discloses lactobacillus rhamnosus CCFM1252 capable of producing sulforaphane through metabolism to relieve inflammatory response, and belongs to the technical field of microorganisms. The invention provides a strain of Lactobacillus rhamnosus CCFM1252 which has relatively strong glucoraphanin metabolism capability and can biologically convert sulforaphane, the Lactobacillus rhamnosus CCFM1252 provided by the invention can be used for improving ulcerative colitis and / or systemic inflammation symptoms independently or in combination with sulforaphane, can relieve weight loss during ulcerative colitis, and can be used for treating ulcerative colitis and / or systemic inflammation symptoms. Mucosal injury, reduction of the oxidative stress level of colon, regulation of the transcription level of colon proinflammatory factors, and reduction of release of the proinflammatory factors; and the polypeptide has the potential of reducing the oxidative stress level, reducing the release of proinflammatory factors and relieving the injury of colon, liver and the like.

The invention discloses an application of an osrodendranthus spicatus(Thunb.)C.Y.Wu leaf extract in preparation of drugs for treating renal injury. Tests confirm that OS has a regulating effect on mice chronic renal injury induced by high fat diet; different doses of OS can reduce mice renal injury induced by high fat diet to different degrees; the effect of the OS with high dose (500 mg / kg) is the most obvious, and the effect is closely related to a fact that the OS can well reduce high blood fat and oxidative stress levels in the mice with high fat diet. Therefore, the srodendranthus spicatus(Thunb.)C.Y.Wu leaf extract has wide application in preparation of the drugs for treating renal injury.

The invention discloses a repairing makeup remover containing vitamin B12. The makeup remover comprises: 61.2-95.08 parts of deionized water, 0.05-0.1 part of ethylenediamine tetraacetic acid disodiumsalt, 2-5 parts of glycerol, 0.1-3 parts of butanediol, 0.1-3 parts of propylene glycol, 1-5 parts of poloxamer, 0.5-5 parts of disodium cocoamphodiacetate, 0.3-3 parts of ethoxylated esters, 0.3-1.5parts of maltodextrin, 0.1-2 parts of trehalose, 0.1-1 part of perilla leaf extract, 0.1-1 part of kapok extract, 0.1-1 part of sweet marijoram leaf extract, 0.2-5 parts of C5-C6 glycols, 0.1-2 partsof capryl glycol, 0.1-0.3 part of cetyl pyridine chloride monohydrate, 0.005-0.15 part of citric acid, 0.005-0.3 part of sodium citrate and 0.001-0.5 part of vitamin B12.

The invention discloses an application of dracocephalum moldavica total flavonoids to preparation of a drug for preventing and treating the AD (Alzheimer's disease). An AD mouse model is established through hypodermic injection of sodium nitrite / D-galactose, the learning and memory capacity and biochemical indexes are scientifically assessed through mouse positioned navigation tests and space exploration tests, it proves that the dracocephalum moldavica total flavonoids can improve the space learning and memory capacity of AD model mice, dose dependence is formed, escape incubation of the AD mice is shortened, and platform crossing times in the space exploration tests are significantly increased; meanwhile, the content of MDA in cortical tissue in the AD mice can be significantly decreased, the content of SOD can be significantly increased, and the oxidative stress level in brain tissue can be reduced; also, through reduction of expression of pro-inflammatory factors IL-1beta and TNF-alpha, inflammatory injuries to the brain tissue can be relieved, the neuron protection role can be played, and the learning and memory capacity of the AD mice can be improved finally. Thus, a reference basis can be provided for clinic application of the dracocephalum moldavica total flavonoids in the future.

The invention discloses application of a nucleotide mixture in preparation of a preparation for preventing or relieving senile sarcopenia, and belongs to the field of medicine and health care. The nucleotide mixture consists of five kinds of 5'-mononucleotides or sodium salts thereof, and the mass ratios of CMP, AMP, UMP, GMP and IMP acid types converted by each kind of nucleotide are respectively as follows: 23-78% of CMP, 6-44% of AMP, 7-40% of UMP and 7-51% of GMP, and IMP is 0 or is greater than 0 but not greater than 2.5%. Nucleotide molecular weight is small, absorption is fast after the nucleotide mixture is taken by the human body, and bioavailability is high. The invention discovers that the intake nucleotide can improve the skeletal muscle function of the old body and increase the muscle mass by eliminating the mitochondrial dysfunction and reducing the oxidative stress so as to perform the functions of sarcopenia prevention and treatment, and a new way for preparing medicines or functional foods for preventing and treating the sarcopenia is provided.

The invention belongs to the technical fields of biology and medicine, and particularly relates to application of Nano-MitoPBN in preparing medicines for resisting oxidation and treating diabetes. Dueto the micro-compartmentalization effect, Nano-MitoPBN can remove mitochondrion superoxide / hydrogen peroxide generated by single electron leakage of a liver mitochondrion electron transport chain, increase the respiration rate of a mitochondrion state 3 and the respiration control ratio, improve synthesis of ATP, and promote the function of mitochondria. In addition, by reducing ROS, Nano-MitoPBNreduces gluconeogenesis, increases glycolysis, reverses ROS-mediated liver glycometabolism reprogramming in diabetic animals, then reduces the peripheral blood glucose level of the diabetic animals and restores the glucose tolerance of the diabetic animals. Nano-MitoPBN serves as a material for preparing the medicines for treating diabetes, can be used for targeting liver prevention and relievingand treating diabetes, and can obtain a remarkable curative effect with a very small dosage.

The invention relates to the field of health-care food, in particular to a bifidobacterium longum dietary composition for intervening chronic nephritis and uremia and the application thereof. The bifidobacterium longum dietary composition comprises 100mL of bifidobacterium longum BLG301 probiotic milk and 40g of cereal powder tablets. The preparation method comprises the following steps: taking out probiotic powder frozen and preserved at -80 DEG C, cooling to room temperature, adding the probiotic powder into the pasteurized cow milk; the product prepared by the preparation method of the bifidobacterium longum BLG301 probiotic cow milk and cereal powder tablets are jointly used as diet collocation, so that oxidative stress in intestinal tracts of human bodies is improved, and the levels of inflammatory factors and urotoxin in the human bodies are reduced. Compared with the prior art, the probiotics are adopted to intervene chronic nephritis, so that the oxidative stress level of patients with chronic nephritis can be reduced; the inflammatory factor level and the uremic toxin level of a chronic nephritis patient are improved; the pH value of the excrement is improved, the organic acid content of the excrement is increased, intestinal flora is healthier, beneficial bacteria are increased, harmful bacteria are reduced, and the flora structure is more beneficial to intestinal health.

The invention discloses an application of FUNDC1 in treating acute respiratory distress syndrome and belongs to the technical field of biology. The present invention provides the application of the FUNDC1 in preparing products for preventing and / or treating inflammatory diseases. The mechanism of the FUNDC1 in preventing and / or treating inflammatory diseases is mainly to reduce lung injury by mediating mitochondrial autophagy to inhibit activation and expansion of inflammatory reactions induced by an ROS-NLRP3 signaling pathway. The invention provides the application of the FUNDC1 in preparingproduct for preventing and / or treating acute respiratory distress syndrome. The product provided by the invention can reduce lung injury by inhibiting inflammatory reactions by promoting autophagy during ARDS period. The FUNDC1 is expected to become a new target for ARDS treatment and has a wide application prospect.

The invention discloses a new use of sodium pyruvate, namely application in the preparation of a storage liquid for improving stored erythrocyte quality and / or post-infusion tissue damage.The sodium pyruvate is used as an active ingredient to prepare the storage liquid for improving stored erythrocyte quality and / or post-infusion tissue damage, it is possible to improve the stored erythrocyte quality and / or post-infusion tissue damage, the therapeutic effect is significant, no side effect occurs, safety is good, and the sodium pyruvate plays an important role in studying and developing this storage liquid and has promising application prospect and great social significance.

The invention belongs to the field of food processing, and relates to the technical field of health-caring nutrition products; and the invention specifically relates to konjac nutrition powder and konjac capsules containing the konjac nutrition powder with a nutrient-enriching function. The konjac nutrition powder comprises the following raw-material ingredients: konjac powder and a nutrition fortifier; content of konjac glucomannan in the konjac powder is 50-70%; and the nutrition fortifier comprises vitamin A acetate, vitamin D3, riboflavin, pyridoxine hydrochloride, cobalamin, nicotinamide, calcium carbonate, ferrous fumarate, vitamin E acetate, and ascorbic acid. After entering the intestines and the stomach, the konjac powder is capable of expanding by absorbing water so as to increase satiety. The nutrition fortifier solves the problem of liable nutrient deficiency caused by long-term intake of the konjac powder. The konjac nutrition powder and the konjac capsules containing the konjac nutrition powder with the nutrient-enriching function are especially suitable for people with the demand of losing weight.

The invention discloses application of all-cannabinoid in preparation of a drug for treating a Parkinson's disease (PD). The all-cannabinoid is prepared by uniformly mixing, by weight, 0.3-99.7 parts of an industrial hemp seed extract with 99.7-0.3 parts of industrial cannabinoids. Experiments prove that the prepared all-cannabinoid has the effects of removing free radicals, inhibiting lipid peroxidation and enabling generation and removal of oxygen radicals to be in dynamic balance to slow disease progress of the PD. The all-cannabinoid has a good application prospect on preparation of the drug for treating the Parkinson's disease.

The invention provides application of a pharmaceutical combined preparation and traditional Chinese medicine composition in preparation of a chemotherapeutic drug synergistic attenuated agent, and relates to the technical field of medicine. The pharmaceutical combined preparation provided by the invention comprises a chemotherapeutic medicine and a traditional Chinese medicine composition. Compared with single usage of chemotherapeutic drugs, the pharmaceutical combined preparation can effectively improve the appetite suppression, mental state difference and weight loss which are easy to occurin cancer patients during a chemotherapy process, without significant influence on tumor inhibition rate. At the same time, the pharmaceutical combined preparation can effectively enhance the body'soxidative free radical scavenging power and avoid the intensification of the body cell damage. Moreover, the pharmaceutical combined preparation can also improve the stimulation and damage of the gastrointestinal tracts by the chemotherapeutic drug, and has the function of protecting the mucosa of the digestive tracts.

The invention discloses a strain of Lactobacillus paracasei capable of relieving alcoholic intestinal damage and an application thereof, belonging to the technical field of microorganisms and the technical field of medicine. The invention provides a medicine that can prevent and / or treat alcohol-induced intestinal damage or alcohol-induced liver damage. The active ingredient of the medicine is Lactobacillus paracasei CCFM1120, and the Lactobacillus paracasei CCFM1120 can effectively relieve Alcohol-induced intestinal injury and alcohol-induced liver injury are embodied in: significantly increasing the mRNA expression of tight junction protein in the intestinal tract of alcoholic model mice; significantly reducing the content of endotoxin in the serum of alcoholic model mice; The activities of alanine aminotransferase and aspartate aminotransferase in the serum of model mice; significantly reduce the level of oxidative stress in the liver of alcohol model mice; significantly improve the pathological damage of alcohol model mice liver tissue.

Synthetic ionophores for the active carry and transport of free ions across biological membranes in vivo, comprising coordination complexes of molecules with polarized hexa-aqua and / or tetra-aqua systems of free ionic metals and ionic salts as the ionophores, useful in transporting pharmaceutical, nutrient, and personal healthcare compounds. Also described are methods of their administration, methods of their synthesis and manufacture, and the ionophore products of such synthesis and manufacturing methods.

The invention discloses a novel application of polypeptide Humanin, namely an application of a polypeptide Humanin gene as an action target in screening and preparing a medicine for treating polycystic ovarian syndrome, or an application of polypeptide Humanin in preparing a medicine for treating polycystic ovarian syndrome. Experimental results show that the exogenous supplementation of Humanin polypeptide can obviously reduce the weight of a PCOS rat, reduce the androgen level of the PCOS rat, improve the ovulation state and reduce the systematic and partial oxidative stress level of the PCOS rat; the exogenous supplementation of Humanin polypeptide can obviously reduce fasting blood glucose and fasting insulin levels of the PCOS rat, and reverse abnormal conduction of a glycometabolismpathway IRS1 / PI3K / AKT and abnormal protein expression of GLUT4 in ovarian granular cells of the PCOS rat; the polypeptide Humanin gene provides possibility for developing polycystic ovarian syndrome drugs based on the polypeptide Humanin gene in the future, and the invention has great application value and prospect.

The invention belongs to the technical field of Chinese patent medicines, and relates to pharmaceutical use of a hirudo and rhizoma ligustici capsule in treatment of non-alcoholic fatty liver disease(NAFLD). The hirudo and rhizoma ligustici capsule is prepared from hirudo, rhizoma ligustici, radix puerariae, herba leonuri and radix salviae miltiorrhizae at the ratio of 1 to 1 to 1 to 1 to 1. According to the pharmaceutical use, high fat diet (HFD) induced rat NAFLD model is adopted for studying the treatment effect of ZXC on rat NAFLD, it is found that ZXC can significantly reduce the blood lipid level of the model rat, significantly relieve liver fat caused by HFD, alleviate liver injury, reduce oxidative stress level of liver, and have high medicinal value.

The invention discloses a new use of sodium pyruvate, namely application in the preparation of a storage liquid for improving stored erythrocyte quality and / or post-infusion tissue damage.The sodium pyruvate is used as an active ingredient to prepare the storage liquid for improving stored erythrocyte quality and / or post-infusion tissue damage, it is possible to improve the stored erythrocyte quality and / or post-infusion tissue damage, the therapeutic effect is significant, no side effect occurs, safety is good, and the sodium pyruvate plays an important role in studying and developing this storage liquid and has promising application prospect and great social significance.

The invention belongs to the technical field of Chinese patent medicines, and relates to the medical application of a compound Chinese patent drug Zhixiong capsules for treating fatty liver, in particular to the application of Zhixiong capsules in the preparation of medicines for treating non-alcoholic fatty liver disease (NAFLD). The Zhixiong capsule is composed of leech, Chuanxiong, kudzu root, motherwort and salvia miltiorrhiza, wherein leech: Chuanxiong: kudzu root: motherwort: salvia = 1:1:1:1:1. The present invention adopts a high-fat diet (HFD)-induced rat NAFLD model to study the therapeutic effect of ZXC on rat NAFLD, and finds that ZXC can significantly reduce the blood lipid level of the model rat, and significantly alleviate the liver fat caused by HFD, and slow down liver damage , reduce the oxidative stress level of the liver, and has good medicinal value.

The invention relates to the application of polydatin in protecting testicular ischemia-reperfusion injury. Repositioning after testicular torsion is a process of ischemia-reperfusion injury, which will affect male reproductive function and even lead to infertility, and there is a lack of effective clinical adjuvant treatment. The anti-oxidative stress activity of polydatin in ischemia-reperfusion injury has been widely studied, especially in tissues such as heart, brain and lung, but the effect and mechanism in testicular ischemia-reperfusion injury have not been reported yet. The invention discloses the application of polydatin as a medicine for treating testicular ischemia-reperfusion injury, which can improve testicular tissue damage, regulate lipid peroxidation and enzymatic antioxidant defense system in the process of testicular ischemia-reperfusion, and relieve testicular ischemia Germ cell apoptosis induced by reperfusion regulates apoptosis-associated proteins in ischemia-reperfused testes. Polydatin has the function of protecting testicular ischemia-reperfusion injury, broadens the research and application of polydatin, and provides new ideas for the treatment of testicular torsion.

The invention relates to the technical field of probiotics, and particularly discloses a novel application of a composite probiotic preparation to the field of oxidation resistance. The composite probiotic preparation can be used for preparing antioxidant products. The composite probiotic preparation disclosed by the invention consists of streptococcus thermophilus S709, lactobacillus paracasei L578 and lactobacillus helveticus L551, can effectively remove oxygen free radicals (DPPH, ABTS, superoxide anion free radicals and hydroxyl free radicals) in vivo and in vitro, effectively reduces the oxidative stress level of cells, improves the activity of SOD and GSH-PX and increases the antioxidant capacity of a matrix, is free from any toxic and side effects, and establishes a foundation for exploring the action mechanism of the probiotics in antioxidation and sleep regulation.

The invention relates to a new application of ethyl p-hydroxybenzoate in pharmacy and belongs to the field of medicine. Ethyl p-hydroxybenzoate has preventive and therapeutic effects on diabetic nephropathy, can inhibit the proliferation of glomerular mesangial cells and apoptosis of endothelial cells induced by AGEs, reduce the level of oxidative stress of endothelial cells induced by AGEs, and improve STZ‑CFA The urine protein, urine creatinine, serum creatinine, creatinine clearance rate, blood sugar and blood pressure of diabetic nephropathy model rats caused by diabetes were abnormal. Ethyl p-hydroxybenzoate can be prepared into a pharmaceutical composition with a drug carrier, and then prepared into various oral dosage forms, such as granules, tablets, capsules, pills, etc., which are easy to use, safe and reliable.

The invention discloses a composition for preventing and treating hyperuricemia and application thereof. The composition comprises an effective amount of carvacrol and an excipient or an additive. Thecomposition can be used for preparing medicines or health products for preventing or treating hyperuricemia and gout. Experiments of control model mice prove that indexes, such as uric acid and creatinine, in hyperuricemia can be remarkably reduced by using the composition. Besides, the composition can protect the kidney functions, prevent kidney tissue lesions and improve the survival rate, andhas good application prospects.

The invention provides an application of a drug combination preparation and a traditional Chinese medicine composition in the preparation of a chemotherapeutic drug synergist and attenuator, and relates to the technical field of medicine. The drug combination preparation provided by the invention includes a chemotherapeutic drug and a traditional Chinese medicine composition. Compared with the single use of chemotherapy drugs, the drug combination preparation can effectively improve the problems of appetite suppression, poor mental state and weight loss in cancer patients during chemotherapy, on the basis of having no significant effect on the tumor inhibition rate. At the same time, the drug combination preparation can also effectively enhance the scavenging ability of the body's oxidative free radicals, and avoid the aggravation of cell damage in the body. Moreover, the drug combined preparation can also improve the stimulation and damage of the digestive tract mucosa caused by chemotherapy drugs, and has the effect of protecting the digestive tract mucosa.